Cargando…

Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D(2/3) receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers

BACKGROUND: Agonist positron emission tomography (PET) tracers for dopamine D(2/3) receptors (D(2/3)Rs) offer greater sensitivity to changes in endogenous dopamine levels than D(2/3)R antagonist tracers. D(2/3)R agonist tracers currently available for clinical research are labeled with the short-liv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shalgunov, Vladimir, van Wieringen, Jan-Peter, Janssen, Henk M., Fransen, P. Michel, Dierckx, Rudi A.J.O., Michel, Martin C., Booij, Jan, Elsinga, Philip H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512978/ https://www.ncbi.nlm.nih.gov/pubmed/26205538 http://dx.doi.org/10.1186/s13550-015-0119-x

Ejemplares similares

Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D(2/3) Receptors
por: van Wieringen, Jan-Peter, et al.
Publicado: (2014)

Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging
por: Shalgunov, Vladimir, et al.
Publicado: (2018)

Agonist signalling properties of radiotracers used for imaging of dopamine D(2/3) receptors
por: van Wieringen, Jan-Peter, et al.
Publicado: (2014)

Allosteric Interactions between Adenosine A(2A) and Dopamine D(2) Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging
por: Prasad, Kavya, et al.
Publicado: (2021)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Effect of Dopamine D(2) Receptor Antagonists on [(18)F]-FEOBV Binding
por: Schildt, Anna, et al.
Publicado: (2020)

A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox
por: Vállez Garcia, David, et al.
Publicado: (2015)

Correction: A Standardized Method for the Construction of Tracer Specific PET and SPECT Rat Brain Templates: Validation and Implementation of a Toolbox
por: Garcia, David Vállez, et al.
Publicado: (2015)

The Crisis After the Crisis: The Time Is Now to Prepare Your Radiology Department
por: Kwee, Thomas C., et al.
Publicado: (2020)

A proof-of-concept study on the use of a fluorescein-based (18)F-tracer for pretargeted PET
por: Helbert, Hugo, et al.
Publicado: (2022)

Impact of an Adenosine A(2A) Receptor Agonist and Antagonist on Binding of the Dopamine D(2) Receptor Ligand [(11)C]raclopride in the Rodent Striatum
por: Prasad, Kavya, et al.
Publicado: (2022)

Test–Retest Repeatability of [(18)F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function
por: García-Varela, Lara, et al.
Publicado: (2020)

Autonomic failure in Parkinson’s disease is associated with striatal dopamine deficiencies
por: van Deursen, Dagmar N., et al.
Publicado: (2020)

Pharmacokinetic Modeling of [(11)C]GSK-189254, PET Tracer Targeting H(3) Receptors, in Rat Brain
por: Ghazanfari, Nafiseh, et al.
Publicado: (2022)

The SPECT tracer [(123)I]ADAM binds selectively to serotonin transporters: a double-blind, placebo-controlled study in healthy young men
por: van de Giessen, Elsmarieke, et al.
Publicado: (2010)

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011)

T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
por: Tamagnan, Gilles, et al.
Publicado: (2018)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Patient safety in nuclear medicine: identification of key strategic areas for vigilance and improvement
por: Kasalak, Ömer, et al.
Publicado: (2020)

Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression
por: de Kwaasteniet, Bart P., et al.
Publicado: (2014)

Novel approach to semi‐quantification of tracer accumulation in dopamine transporter scan
por: Ito, Yoshinori, et al.
Publicado: (2022)

Correction: Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression
por: de Kwaasteniet, Bart P., et al.
Publicado: (2015)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Head-to-head comparison of (R)-[(11)C]verapamil and [(18)F]MC225 in non-human primates, tracers for measuring P-glycoprotein function
por: García-Varela, Lara, et al.
Publicado: (2021)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Effects of 2-bromoterguride, a dopamine D(2) receptor partial agonist, on cognitive dysfunction and social aversion in rats
por: Tarland, Emilia, et al.
Publicado: (2017)

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D(2) and Histamine H(3) Receptors: A PET Study in Healthy Rats
por: Ghazanfari, Nafiseh, et al.
Publicado: (2022)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Lower striatal dopamine D(2/3 )receptor availability in obese compared with non-obese subjects
por: de Weijer, Barbara A, et al.
Publicado: (2011)

In Vivo Induction of P-Glycoprotein Function can be Measured with [(18)F]MC225 and PET
por: García-Varela, Lara, et al.
Publicado: (2021)

Potential PET tracers for imaging of tumor-associated macrophages
por: Fernandes, Bruna, et al.
Publicado: (2022)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications
por: Visser, Anniek K. D., et al.
Publicado: (2010)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use
por: Chalon, Sylvie, et al.
Publicado: (2019)

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors
por: Helgebostad, Rasmus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aln0v2apdibqkkt22ti456roe4